Tovecimig
Clinical Trials Overview
1 trials found
About Tovecimig
Tovecimig is an investigational medication currently being studied in clinical trials for colorectal cancer. It is being evaluated as a potential treatment option for patients whose cancer has spread (metastatic) and has not responded to, or has returned after, one previous round of treatment (second-line therapy). The trials are designed to assess the safety and effectiveness of Tovecimig when given in combination with a standard chemotherapy regimen called FOLFIRI (which includes the drugs 5-Fluorouracil, Irinotecan, and Leucovorin). Tovecimig is not yet approved for use in colorectal cancer and is only available through clinical trials.
Category
Other Medications
Mechanism
The specific way Tovecimig works is still under investigation. It is being studied in combination with FOLFIRI to see if it can improve the effectiveness of this standard chemotherapy regimen in patients with advanced colorectal cancer who have already received one prior treatment. Researchers are evaluating how Tovecimig interacts with cancer cells and the body's response to it.
1
Total Trials
0
Recruiting
0
Active
0
Completed
25
Total Enrollment
1
Countries
NCT07662031
Phase 2
Not yet recruiting
25 patients
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
United States